Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Haematologica

Volumn 98, Issue 1, 2013, Pages 119-128

  Sekeres, Mikkael A ^a   Lancet, Jeffrey E ^b   Wood, Brent L ^c   Grove, Laurie E ^d   Sandalic, Larissa ^d   Sievers, Eric L ^d   Jurcic, Joseph G ^e  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SEATTLE GENETICS INC   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DIPHENHYDRAMINE; HUM 195; LINTUZUMAB; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; BRONCHITIS; CANCER SURVIVAL; CHILL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEATH; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; HYPERTHERMIA; HYPOKALEMIA; HYPOTENSION; LEUKOPENIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TRANSFUSION; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONALITY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872072793     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.066613     Document Type: Article

References (47)

1. National Cancer Institute SEER Stat Fact Sheets: Acute Myeloid Leukemia, available from http://seer.cancer.gov/statfacts/ html/amyl.html.
2. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597-603.
3. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-5.
4. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-85.
5. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001; 98(3):548-53.
6. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417-24.
7. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll, AJ, Vardiman JW, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and longterm outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108 (1):63-73.
8. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-20.
9. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/Pglycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94(3):1086-99.
10. Suarez L, Vidriales MB, Moreno MJ, Lopez A, Garcia-Larana J, Perez-Lopez C, et al. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica. 2005;90(1):54-9.
11. Baz R, Rodriguez C, Fu AZ, Jawde RA, Kalaycio M, Advani A, et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer. 2007;110(8):1752-9.
12. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-87.
13. Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7(9):1268-74.
14. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115(24):5746-51.
15. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272-9.
16. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18(4):809-16.
17. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-9.
18. Blum W, Garzon R, Klisovic RB, Schwind S, Walter A, Geyer S, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473-8.
19. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-61.
20. Thomas XG, Dmoszynska A, Wierzbowska A, Kuliczkowski K, Mayer J, Shelekhova T, et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. ASCO Meeting Abstracts. 2011;29(15_suppl):Abstract 6504.
21. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMulin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-24.
22. Albo C, de la Fuente J, Ares C, Alonso C, Feteira E. Kinetics and immunophenotypic characterization of circulating hematopoietic progenitor cells after peripheral blood stem cell transplantation. Haematologica. 2004;89(7):845-51.
23. Gan OI, Dorrell C, Pereira DS, Ito CY, Wang JC, Dick JE. Characterization and retroviral transduction of an early human lymphomyeloid precursor assayed in nonswitched long-term culture on murine stroma. Exp Hematol. 1999;27(6):1097-106.
24. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984; 8(4):521-34.
25. Tanimoto M, Scheinberg DA, Cordon Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3(5):339-48.
26. Burnett A, Hills R, Hunter AE, Milligan D, Kell WJ, Wheatley K, et al. The addition of gemtuzumab ozogamicin to low dose AraC improves remission rates but not survival: results of the UK LRF AML14 and NCRI AML16 "Pick a Winner" comparison. Blood. 2010;116(21):Abstract 18.
27. Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al. Preliminary results of Southwest Oncology Group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood. 2009;114(22): Abstract 790.
28. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res. 1992;52(24):6761-7.
29. Sutherland MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M, et al. Antileukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs. 2009;1(5):481-90.
30. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized antiCD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res. 1998;4(6):1421-8.
31. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized antiCD33 monoclonal antibody HuM195. Leukemia. 2003;17(2):314-8.
32. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110-6.
33. Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leukemia Lymphoma. 2009;50(8):1336-44.
34. Fröling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108(10):3280-8.
35. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598-605.
36. Webster K, Chivington K, Shonk C, Eremenco S, Yount S, Hahn E, et al. Measuring quality of life (QOL) among patients with leukemia: The Functional Assessment of Cancer-Therapy-Leukemia (FACT-Leu). Qual Life Res. 2002;11(7):678.
37. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
38. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
39. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96(3):870-7.
40. Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer. 2008;112(3):572-80.
41. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086-92.
42. Paul SP, Taylor LS, Stansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood. 2000;96(2):483-90.
43. Vitale C, Romagnani C, Falco M, Ponte M, Vitale M, Moretta A, et al. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci USA. 1999;96:15091-6.
44. Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood. 2011;118(21):Abstract 582.
45. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J-N, et al. Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA). Blood. 2011;118(21):Abstract 6.
46. van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia. 2004;18(5):983-8.
47. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109 (11):4816-24.